文献速递传染病防控与疫情报告免疫规划卫生政策与健康促进

全球黄热病现有与潜在感染风险区的建模分析

Existing and potential infection risk zones of yellow fever worldwide: a modelling analysis.
PubMed 文献 · Lancet Glob Health · 2018-02-02

研究汇集1970至2016年1155条人间黄热病病毒感染地理记录,用泊松点过程提升回归树模型在美洲和非洲47国5×5公里分辨率预测黄热病显性感染相对风险与发病率,并评估风险区外 receptivity 及疫苗接种避免病例数。结果显示国际与次国家尺度空间变异明显,部分高风险区疫苗接种覆盖率低于推荐阈值,2016年接种水平每年在风险区内避免94336至118500例黄热病。

要点

  • 研究用1155条1970至2016年人间黄热病病毒感染地理记录建模预测全球风险区分布。
  • 尼日利亚、刚果民主共和国和南苏丹大部预测年均病例数最高,2016年疫苗接种覆盖率估计远低于推荐防暴发阈值。
  • 2016年接种水平每年在风险区内避免94336至118500例黄热病,基于保守与乐观接种情景。

核心结论

  • 研究结果为在风险区内针对性地开展疫苗接种活动提供了证据基础,并强调其高效性。
  • 研究强调公共卫生当局应最警惕黄热病潜在传播或输入事件的地区。

研究设计与样本

  • 研究汇集1970至2016年1155条人间黄热病病毒感染地理记录。
  • 采用泊松点过程提升回归树模型,纳入环境与生物学解释协变量、疫苗接种覆盖率及疾病报告率空间变异。
  • 在美洲和非洲47国风险区以5×5公里分辨率预测黄热病显性感染相对风险,并预测风险区外地区对黄热病传播引入或再引入的 receptivity。

主要发现

  • 黄热病相对风险与发病率存在明显的国际和次国家空间变异,巴西、喀麦隆和多哥等高风险区疫苗接种降低发病率的成效不一。
  • 尼日利亚、刚果民主共和国和南苏丹大部预测年均病例数最高,2016年疫苗接种覆盖率估计远低于推荐防暴发阈值。
  • 基于保守与乐观接种情景,2016年接种水平每年在风险区内避免94336至118500例黄热病。
  • 预测对黄热病传播高 receptivity 的风险区外地区(如马来西亚、印度尼西亚和泰国部分地区)范围小于主要城市媒介埃及伊蚊的分布,中国南部虽有埃及伊蚊但黄热病传播 receptivity 低。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Yellow fever cases are under-reported and the exact distribution of the disease is unknown. An effective vaccine is available but more information is needed about which populations within risk zones should be targeted to implement interventions. Substantial outbreaks of yellow fever in Angola, Democratic Republic of the Congo, and Brazil, coupled with the global expansion of the range of its main urban vector, Aedes aegypti, suggest that yellow fever has the propensity to spread further internationally. The aim of this study was to estimate the disease's contemporary distribution and potential for spread into new areas to help inform optimal control and prevention strategies. METHODS: We assembled 1155 geographical records of yellow fever virus infection in people from 1970 to 2016. We used a Poisson point process boosted regression tree model that explicitly incorporated environmental and biological explanatory covariates, vaccination coverage, and spatial variability in disease reporting rates to predict the relative risk of apparent yellow fever virus infection at a 5 × 5 km resolution across all risk zones (47 countries across the Americas and Africa). We also used the fitted model to predict the receptivity of areas outside at-risk zones to the introduction or reintroduction of yellow fever transmission. By use of previously published estimates of annual national case numbers, we used the model to map subnational variation in incidence of yellow fever across at-risk countries and to estimate the number of cases averted by vaccination worldwide. FINDINGS: Substantial international and subnational spatial variation exists in relative risk and incidence of yellow fever as well as varied success of vaccination in reducing incidence in several high-risk regions, including Brazil, Cameroon, and Togo. Areas with the highest predicted average annual case numbers include large parts of Nigeria, the Democratic Republic of the Congo, and South Sudan, where vaccination coverage in 2016 was estimated to be substantially less than the recommended threshold to prevent outbreaks. Overall, we estimated that vaccination coverage levels achieved by 2016 avert between 94 336 and 118 500 cases of yellow fever annually within risk zones, on the basis of conservative and optimistic vaccination scenarios. The areas outside at-risk regions with predicted high receptivity to yellow fever transmission (eg, parts of Malaysia, Indonesia, and Thailand) were less extensive than the distribution of the main urban vector, A aegypti, with low receptivity to yellow fever transmission in southern China, where A aegypti is known to occur. INTERPRETATION: Our results provide the evidence base for targeting vaccination campaigns within risk zones, as well as emphasising their high effectiveness. Our study highlights areas where public health authorities should be most vigilant for potential spread or importation events. FUNDING: Bill & Melinda Gates Foundation.

来源:Lancet Glob Health,查看原文。版权归原作者所有。

引用

  1. Shearer FM, Longbottom J, Browne AJ, et al. Existing and potential infection risk zones of yellow fever worldwide: a modelling analysis. Lancet Glob Health. 2018. PMID: 29398634. doi:10.1016/S2214-109X(18)30024-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。